@article{ZellerHeidemeierGrigoleitetal.2017,
  author    = {Zeller, Daniel and Heidemeier, Anke and Grigoleit, G{\"o}tz Ulrich and M{\"u}llges, Wolfgang},
  title     = {Case report: subacute tetraplegia in an immunocompromised patient},
  series = {BMC Neurology},
  volume    = {17},
  journal   = {BMC Neurology},
  number    = {31},
  doi       = {10.1186/s12883-017-0814-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157576},
  year      = {2017},
  abstract  = {Background: Clinical reasoning in Neurology is based on general associations which help to deduce the site of the lesion. However, even "golden principles" may occasionally be deceptive. Here, we describe the case of subacute flaccid tetraparesis due to motor cortical lesions. To our knowledge, this is the first report to include an impressive illustration of nearly symmetric motor cortical involvement of encephalitis on brain MRI. Case presentation: A 51 year old immunocompromized man developed a high-grade pure motor flaccid tetraparesis over few days. Based on clinical presentation, critical illness polyneuromyopathy was suspected. However, brain MRI revealed symmetrical hyperintensities strictly limited to the subcortical precentral gyrus. An encephalitis, possibly due to CMV infection, turned out to be the most likely cause. Conclusion: While recognition of basic clinical patterns is indispensable in neurological reasoning, awareness of central conditions mimicking peripheral nervous disease may be crucial to detect unsuspected, potentially treatable conditions.},
  language  = {en}
}
@article{LapaKircherHaenscheidetal.2018,
  author    = {Lapa, Constantin and Kircher, Malte and H{\"a}nscheid, Heribert and Schirbel, Andreas and Grigoleit, G{\"o}tz Ulrich and Klinker, Erdwine and B{\"o}ck, Markus and Samnick, Samuel and Pelzer, Theo and Buck, Andreas K},
  title     = {Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients},
  series = {Theranostics},
  volume    = {8},
  journal   = {Theranostics},
  number    = {3},
  doi       = {10.7150/thno.22161},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158983},
  pages     = {644-649},
  year      = {2018},
  abstract  = {Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10\% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors. Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT. Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient \#1) and stable disease regarding morphology as well as disease activity (patient \#2), respectively. Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.},
  language  = {en}
}
@article{IsbernerKrausGrigoleitetal.2021,
  author    = {Isberner, Nora and Kraus, Sabrina and Grigoleit, G{\"o}tz Ulrich and Aghai, Fatemeh and Kurlbaum, Max and Zimmermann, Sebastian and Klinker, Hartwig and Scherf-Clavel, Oliver},
  title     = {Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial},
  series = {Cancer Chemotherapy and Pharmacology},
  volume    = {88},
  journal   = {Cancer Chemotherapy and Pharmacology},
  number    = {6},
  issn      = {1432-0843},
  doi       = {10.1007/s00280-021-04351-w},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266476},
  pages     = {973-983},
  year      = {2021},
  abstract  = {Purpose Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects. Methods 262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed. Results Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6-99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p < 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50\%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15\% (p < 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p < 0.05). Conclusion Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity.},
  language  = {en}
}